Our Corporate Sponsors

Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.

Our Corporate Sponsors

Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.

Meet Our 2023 Sponsors

Tetra Therapeutics logo, an NFXF sponsor.

Tetra Therapeutics

Tetra Therapeutics, a Shionogi Group Company, is a clinical-stage biotechnology company focused on developing a portfolio of therapeutic products for people suffering from Fragile X syndrome, Alzheimer’s disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is headquartered in Grand Rapids, Michigan.

Zynerba Pharmaceuticals logo, an NFXF sponsor.

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Zynerba is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome, and autism spectrum disorder.

Asuragen logo

Asuragen

Asuragen, a BioTechnique brand, takes the complexity out of Fragile X by offering Fragile X diagnostic genetic testing. Testing for Fragile X syndrome is important, especially for women who are pregnant or plan to become pregnant.

Allos Pharma

Allos Pharma

Allos Pharma is a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Their work spans three decades of research in neuroscience and intellectual disabilities.

Anavex Life Sciences logo

Anavex

Anavex Life Sciences Corp is working to develop novel small molecule treatments for some of the most challenging central nervous system (CNS) diseases facing society today, including Alzheimer’s, Parkinson’s, Rett syndrome, and other rare diseases.

Autifony Therapeutics logo

Autifony

Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.

Sponsor Benefits

Kristin Bogart
Interested in learning more about our Corporate Sponsorship program?

If you have questions, we’d love to hear from you! You can reach out to Kristin Bogart directly, or submit your question or comment through our contact form.

Kristin Bogart,
Senior Director, Development and Communications
kristin@fragilex.org
202-747-6209